{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:20Z","timestamp":1781049440772,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA215105"],"award-info":[{"award-number":["CA215105"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In\u2010transit metastases (ITM) are a form of locoregional relapse representing intralymphatic metastatic spread and occur in approximately 4\u20139% of patients with melanoma &gt;1\u2009mm Breslow thickness. Our objective was to evaluate a combination of clinicopathologic risk factors and gene expression biomarkers predictive of ITM risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used PCR to quantify gene expression in diagnostic biopsy tissue across a prospectively designed archival cohort of 854 consecutive thin and intermediate thickness primary cutaneous melanomas. The outcome of interest was ITM &gt;90\u2009days after a melanoma diagnosis. Cox proportional hazard models were fit to estimate each clinicopathologic and molecular characteristic\u2019s association with the risk of ITM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 5\u2010year cumulative incidence of ITM was 3.2%. Clinical factors univariately associated with an increased risk of ITM were older age, greater Breslow thickness, greater mitotic rate, lower extremity location, ulceration, and a positive SLN biopsy. Of 108 genes tested, five were significantly upregulated and five significantly downregulated when evaluated in Cox models adjusted for age, Breslow thickness, mitotic rate, and lower extremity location. Among the upregulated genes, the strongest association was observed for interleukin\u20108 (IL8).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A subset of gene expression biomarkers was identified as independently associated with the risk of ITM after adjusting for key covariates. Once sufficiently validated, our results may lead the way to regional therapy trials for a small, selected group of high\u2010risk patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.16141","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T09:10:41Z","timestamp":1646471441000},"page":"1117-1123","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of tumor molecular factors with in\u2010transit metastasis in primary cutaneous melanoma"],"prefix":"10.1111","volume":"61","author":[{"given":"James W.","family":"Jakub","sequence":"first","affiliation":[{"name":"Department of Surgery Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Weaver","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-8288","authenticated-orcid":false,"given":"Alexander","family":"Meves","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4100-0"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.05.025"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.20.537"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.08.012"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25330"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0"},{"key":"e_1_2_5_8_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma: Cutaneous 2.2022","year":"2022"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15125"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.05.012"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00206"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-13"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-199201000-00013"},{"key":"e_1_2_5_15_1","first-page":"113","volume-title":"Carcinoma of the Colon and Antecedent Epithelium","author":"Folkman J","year":"1970"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/222033a0"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.152.3727.1397"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2906"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1281554"},{"key":"e_1_2_5_20_1","first-page":"2970","article-title":"[corrigendum] IL\u20108 promotes proliferation and inhibition of apoptosis via STAT3\/AKT\/NF\u2010\u03baB pathway in prostate cancer","volume":"19","author":"Guo Y","year":"2019","journal-title":"Mol Med Rep"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01223"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0193"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2016.08.002"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.029"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01246-4"},{"key":"e_1_2_5_27_1","first-page":"A419","article-title":"394 Interleukin\u20108\u2013neutralizing monoclonal antibody BMS\u2010986253 plus nivolumab (NIVO) in biomarker\u2010enriched, primarily anti\u2013PD\u2010(L)1\u2013experienced patients with advanced cancer: initial phase 1 results","volume":"8","author":"Davar D","year":"2020","journal-title":"J Immunother Cancer"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.67.1.53"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.16141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:12:07Z","timestamp":1713168727000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/ijd.16141"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16141","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]},"assertion":[{"value":"2021-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}